Myasthenia Gravis (MG)

Myasthenia Gravis (MG)

Myasthenia Gravis and you

Welcome to the MG area of the J&JWithMe platform, dedicated to helping people understand more about myasthenia gravis (MG).

Receiving a diagnosis of MG can be overwhelming, since the disease can affect not only your physical abilities but also your overall quality of life. MG is characterised by weakness in the voluntary muscles, which are muscles consciously controlled by the brain. Because these muscles are attached to the skeleton throughout the body and control body movement, people living with MG can find daily physical activities challenging. The symptoms of MG are often unpredictable and may fluctuate, which requires adjustments in everyday activities to accommodate the symptoms when living with the disease.

By enhancing understanding of MG, its symptoms and the treatment options available, people living with MG, as well as their carers and loved ones, can play a more active role in care, should they wish. Knowledge and understanding of MG can empower people living with the condition and their caregivers to make informed decisions during medical consultations and to tailor care plans according to specific needs.

Here, we aim to provide trusted and reliable information to help further understanding about the journey of living with MG. More updates are planned for this website, so stay tuned over the coming months. For specific medical advice, always consult your healthcare team as your first point of contact.

Patient Perspective

“My symptoms with myasthenia [MG] can vary from hour to hour, day to day, week to week, month to month. There's no knowing one day how I'm going to feel later on in the same day. I might have reasonably well-controlled symptoms in the morning, but by the evening I may not be able to get up and down the stairs. So, every day is a little bit of its own adventure with symptoms of myasthenia, and there's really no predictability.” – MG Patient, UK

Key topics

About MG
Gain an overview of MG, what it is, what causes it and the path to an MG diagnosis.

References

Global Patient and Carer Experience Survey. (2021). Available at: https://www.clladvocates.net/wp-content/uploads/2023/09/Global-Leukemia-Experience-Survey_Full-Report.pdf. Last accessed: November 2024.
Alu, Aqu et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology. 2022 Oct;15:138.
Tam CS, et al. Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial. Curr Med Res Opin. 2023 Sep:1-7.
Eichhorst B, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35(9):762-768.
DrugBank Online. Warfarin. Available at: https://go.drugbank.com/drugs/DB00682. Last accessed: November 2024.
Lipsky A, et al. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020 Dec;2020(1):336-345.
Cancer Research UK. Ibrutinib (Imbruvica). Available at: https://www.cancerresearchuk.org/about-cancer/treatment/drugs/ibrutinib. Last accessed: November 2024.
Macmillan Cancer Support. Ibrutinib (Imbruvica). Available at: https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/ibrutinib. Last accessed: November 2024.
Quartermaine C, et al. (2023). Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology, 5(5), pp.570–590.
Zeynep Tuğba Güven. CLL-256 Monocytosis Developing in the Course of Chronic Lymphocytic Leukemia: Case Report. 2024;24;Sup 1: S349-S350.
Valla K, et al. Atrial Fibrillation: Considerations for the Use of BTK Inhibitors. Cancer Network Oncology. 2018 Nov; 32(11):574-575.
Logo Janssen | Pharmaceutical Companies of Johnson & Johnson